|
|
||||||||
Unité 365 INSERM, Institut Curie, Paris, France
Correspondence: B. Bauvois, Unité 365 INSERM, Institut Curie, Pavillon Pasteur, 26 rue dUlm, 75231 Paris cedex 05, France. E-mail: bbauvois{at}curie.fr
| ABSTRACT |
|---|
|
|
|---|
Key Words: ADAM ectopeptidase meprin MMP proteinase secretase
| INTRODUCTION |
|---|
|
|
|---|
Several families of membrane proteases are distinguishable on the basis
of their different chromosomal and/or structural organizations, and/or
functions (Table 1
). There are the ectopeptidases [1
2
3
], the
membrane-type matrix metalloproteinases (MT-MMPs)
[4
5
6
7
], the ADAM (a disintegrin and metalloprotease)
family [8
9
10
], the meprins [11
12
13
], and
the secretases (also termed sheddases or convertases)
[14
]. To date, secretases were grouped according to
their capacity to release proteins specifically from the cell surface
[14
]. However, recent cloning of the secretase tumor
necrosis factor
(TNF-
) convertase (TACE) led to its
identification as an ADAM protein, raising the idea that some
secretases may belong to the ADAM family [15
,
16
]. Future cloning of secretases should settle this
question. In this review, we will distinguish secretases from ADAMs,
but the reader should be aware of their possible relation.
|
|
| STRUCTURAL DIVERSITY |
|---|
|
|
|---|
|
-glutamyl
transpeptidase, and angiotensin-converting enzyme [1
2
3
,
22
]; and two MT-MMPs (MT1-MMP and MT4-MMP)
[20
, 21
, 23
]. The patterns of
expression of these proteases have been reviewed previously
[2
, 6
, 8
, 13
,
14
, 24
]. They are regulated tightly during
fetal/postnatal development, tissue repair, inflammation, and disease
[2
, 6
, 8
, 13
,
14
, 24
]. Various growth factors and
cytokines can control their expression by inducing or repressing their
levels of gene transcription and/or protein synthesis [3
,
6
, 8
, 9
, 13
,
14
]. Finally, soluble isoforms of ectopeptidases,
meprins, and ADAMs with undefined functions are found in biological
fluids [3
, 8
, 9
,
25
, 26
].
The ectopeptidases
So far, about 20 ectopeptidases have been identified
[1
2
3
]. They are anchored in the plasma membrane with
the N-terminus (type I) or the C-terminus (type II), facing
extracellularly or through the glycosylphosphatidylinositol (GPI)
moiety. Based on their amino acid sequences, ectopeptidases have been
classified according to their catalytic mechanism: the serine
peptidases characterized by the catalytic amino acid triad His, Asp,
and Ser; the metallodependent peptidases; and a group containing
enzymes for which the mechanism remains undefined, such as
-glutamyltranspeptidase [3
]. Their recognized role
concerns their capacity to modulate bioactive-peptide responses
[1
2
3
]. A cysteine-rich domain is present in the
ectopeptidase dipeptidylpeptidase IV (DPPIV), which interacts with
collagen and fibronectin of the extracellular matrix (ECM; Fig. 1
)
[2
, 3
, 27
]. To date, no
endogenous inhibitors of ectopeptidases have been characterized.
The MT-MMPs
The secreted MMPs are multidomain, zinc-dependent endopeptidases
that share a basic structural organization comprising a prometallo
domain, a metallo domain, and a hemopexin-like domain [4
,
28
29
30
31
]. The prometallo domain maintains the
metalloprotease domain in an inactive state until it is cleaved off.
Their natural inhibitors are
-macroglobulins and TIMPs (tissue
inhibitors of metalloproteases) [28
29
30
31
]. The
contribution of MMPs is the destruction of a variety of molecules
constituting the ECM, including collagens, fibronectin, laminin,
proteoglycans, and others [29
, 31
]. Over
recent years, the MMP family has been expanded to include a new
subfamily of membrane-tethered MMPs known as MT-MMPs [5
,
6
, 18
19
20
, 32
33
34
]. MT(1, 2, 3,
5)-MMPs contain a membrane-spanning sequence in the fourth and last
pexin-like repeat of the carboxy-terminal domain [4
5
6
7
]
(Fig. 1)
, and MT4-MMP and MT6-MMP are anchored into the plasma membrane
through the GPI moiety [34
, 35
]. MT1-MMP is
implicated in the activation of the latent form of secreted
progelatinase A (proMMP-2) [4
, 7
,
36
]. Some MT(1, 2, 3)-MMPs can also be involved in the
proteolysis of ECM [6
, 10
,
17
]. New functions for TIMPs are emerging based on the
interaction of TIMP-2 with MT1-MMP (in its catalytic domain) and
soluble pro-MMP-2 (in its hemopexin-like domain) [37
].
This interaction could lead to the formation of a ternary complex
thought to cluster pro-MMP-2 at the cell surface near a TIMP-free,
active MT1-MMP, which initiates activation of pro-MMP-2
[36
37
38
].
The ADAMs
Like the MT-MMPs, the ADAMs belong to the metzincin
superfamily of Zn-dependent metalloproteinases [8
9
10
].
They have also been referred to as MDCs (metalloproteinase disintegrin
with cysteine-rich domains). The name of disintegrin refers to the
disruption of integrin binding, because the disintegrin domain of
ADAM-15 containing a RGD (Arg-Gly-Asp) motif was shown
initially to inhibit platelet aggregation by competing with the
integrin
IIbß3 [8
9
10
]. The basic structure of an
ADAM protein is well-conserved phylogenically, containing a disintegrin
and a metalloprotease domain as well as a prodomain
[8
9
10
] (Fig. 1) . A subset of the ADAMs (ADAMs-9, -10,
-12, -17) contains the distinctive, zinc-binding consensus HEXXH
(His-Glu-Xaa-Xaa-His) sequence in the metalloprotease domain, and they
are active enzymes following the cleavage of the prodomain by a
furin-type protease [8
9
10
, 39
]. The
disintegrin domain contains the RGD motif recognized by integrins or a
non-RGD motif [8
9
10
]. For example, ADAM-15, expressed
in a wide variety of cells including human leukocytes, exhibits RGD
[8
], and ADAM-2 and ADAM-9 contain an electron capture
detection (Glu-Cys-Asp) motif [40
41
42
]. A limited number
of ADAMs, like ADAM-12, possess a cysteine-rich domain involved in
cell-cell fusion and/or an epidermal growth factor (EGF)-like domain
[43
] (Fig. 1)
. Usually, ADAMs are inhibited by
ethylenediaminetetraacetate (EDTA) and o-phenanthroline, which
chelate Zn2+ ions [8
9
10
, 17
]. Several
studies in vitro and in vivo have shown that
ADAMs are involved in the proteolysis of integral membrane proteins and
ECM as well as in adhesive interactions [8
9
10
].
Unexpectedly, the endogenous inhibitors of MMPs (TIMP-1 and TIMP-3) can
inhibit ADAM-10 and ADAM-17 at least [8
,
44
].
The meprins
The meprins belong to the astacin family of metalloendopeptidases.
They are multidomain, oligomeric proteases, composed of
and/or ß
subunits that are related evolutionarily [11
12
13
]. The
two subunits have similar, multidomain structures (Fig. 1)
, containing
a terminal, signal-peptide sequence, a propeptide sequence, and the
protease domain [11
12
13
]. The catalytic domain is
followed by a cysteine-rich domain and an EGF-like domain
[11
12
13
]. It is interesting that the cytosolic domain of
the ß subunit contains a consensus sequence for phosphorylation by
protein kinase C (PKC) [12
, 13
]. Different
amino acid hydroxamates have been found to inhibit meprins, with
aromatic hydroxamates being the most effective [13
].
Meprins are able to degrade ECM proteins such as collagen and gelatin,
hormones, and several biologically active peptides [11
,
45
].
The secretases
The term "secretase" for the membrane proteases that release
soluble isoforms of membrane proteins was used first a few years ago by
Hooper et al. [14
] following their
characterization of an integral protease able to shed the cell-surface,
angiotensin-converting enzyme (ACE; Fig. 1
). Secretases are involved in
the shedding of the ectodomain of various membrane proteins with a type
I and type II structure at a cleavage site located close to the
membrane [14
, 17
]. Many secretase
activities can be inhibited by metal-chelating agents and by certain
hydroxamic, acid-based compounds, suggesting that secretases are zinc
metalloproteases [14
]. Because TIMPs fail to inhibit
secretase-mediated events, it has been assumed that secretases are
distinct from the MMP family [14
]. Recently, the
secretase involved in the release of TNF-
from the cell surface,
i.e., TACE, was isolated and cloned, and it was found to belong to the
ADAM family [15
].
| FUNCTIONAL REDUNDANCY |
|---|
|
|
|---|
|
Shedding membrane proteins
Many integral membrane proteins lead a dual existence as
membrane-bound and soluble counterparts in vivo, as
indicated by their detection in blood, seminal plasma, urine, milk,
cerebrospinal, and amniotic fluids [25
]. At least two
different mechanisms may generate soluble and membrane-bound isoforms
of the same protein: 1) by alternative splicing and 2) by
posttranslational release of the extracellular domain of membrane
proteins by hydrolytic cleavage of the membrane anchor
[25
]. Hydrolysis involves cleavage of the glycolipid of
GPI-anchored proteins by phospholipases or limited proteolysis of
membrane proteins at a site adjacent to the membrane-spanning sequence
by proteases [25
].
Various proteolytic activities, including metallopeptidase and
serine-protease activities, have been implicated in this process
[14
, 17
, 25
]. Various
cell-surface proteins are released, such as interleukin-6 (IL-6)
receptors, TNF receptors, Fas ligand, transforming growth factor-
(TGF-
), CD23, and CD30 [14
, 25
,
47
]. Examples of protein shedding involving the interplay
of different metalloprotease families are presented below (Table 3)
.
Release of pro-TNF-
The inflammatory cytokine TNF-
is produced as a 26-kDa
transmembrane protein and released as a 17-kDa, soluble TNF-
.
Initial observations indicated that TNF-
was released through the
action of a metallosecretase, known as TACE [14
,
17
]. Other groups have identified ADAM-10 and ADAM-17 as
candidates for the release of soluble TNF-
[8
,
48
]. TACE was cloned subsequently and found to be ADAM-17
[15
]. More recently, the recombinant form of MT4-MMP has
also been shown to shed pro-TNF-
when cotransfected in COS-7 cells
[21
]. Together, these observations underline the fact
that a given substrate may be acted on by various membrane proteases.
Release of ß-amyloid precursor protein (APP)
Cleavage of the transmembrane APP by three different proteolytic
enzymes,
-, ß-, and
-secretases, gives rise to three peptides,
two of them (resulting from the action of ß- and
-secretases)
being the major components of amyloid plaques, which are involved in
the pathogenesis of Alzheimers disease [14
,
17
, 49
]. In contrast, processing APP at the
-secretase site precludes cleavage by the ß- and
-secretases
and thus formation of the respective peptides [14
,
17
, 49
]. ADAM-10 and ADAM-17/TACE can also
function as
-secretases (14, 17) [Table 3
].
Release of cell-adhesion molecules
Many cell-surface molecules such as integrins, selectins, members
of the immunoglobulin superfamily (CD43/sialoadhesin), and CD44 are
implicated in cell-cell and cell-matrix contacts
[50
51
52
]. Adhesion may be altered in different
conditions such as inflammation, wound healing, or the host response to
infections [53
, 54
]. Soluble forms of
L-selectin, CD43, CD44, and integrin
4 have been identified
[25
]. Initial studies indicated that release of
L-selectin from the leukocyte surface was mediated by a membrane-bound
metalloproteinase distinguishable from known MMPs and termed L-selectin
sheddase or L-selectin secretase [55
]. ADAM-17 could
also contribute to L-selectin shedding from human leukocytes
[56
].
Release of membrane proteases themselves
Instead of soluble meprins, which are generated by an alternative
splicing pathway [26
], many ectopeptidases
[3
, 25
] and ADAMs [8
] are
released from the cell surface by specific, post-translational shedding
mechanisms. Whether a given membrane protease can shed itself or is
shed by another membrane protease and hence influences cell behavior
has to be considered. The ectopeptidase ACE is released by an ACE
secretase, which is distinct from ADAM-17/TACE and
secretase
[14
, 17
].
Cell migration
Cell migration is essential for development, inflammation, and
tissue repair, but it also allows malignant cells to exert their lethal
ability to invade tissues and metastasize. Cell migration is linked
intrinsically to concomitant cell adhesiveness and localized
degradation of the ECM. Examples of the involvement of membrane
proteases in cell adhesion and in ECM degradation are described below.
Extracellular matrix degradation
Like secreted MMPs and the serine proteinases cathepsin G,
elastase, and plasminogen activators [57
58
59
60
], membrane
proteases may also contribute to ECM degradation by virtue of their
localization in membrane structures that contact the ECM. Several ADAMs
(-10, -12, -17) and MT-MMPs (-1, -2-, 3), meprin A, and the
ectopeptidase fibroblast activation protein
(FAP-
) are involved
directly in the degradation of collagen type IV, which is abundant in
inflamed tissues [3
, 6
, 8
,
10
, 13
] (Table 3)
. The rat DPPIV, which
cleaves peptide bonds normally after penultimate proline, has been
suggested to exhibit endopeptidase activity toward denatured collagen
[61
]. The ectopeptidase APN and the MT1-MMP are
implicated indirectly in collagen breakdown by inducing the secretion
of type IV epithelial collagenase [62
] and the
activation of soluble proMMP-2 [5
], respectively.
Cell adhesion
Consistent with their proteolytic activity toward collagen, it is
conceivable that membrane proteases such as ADAMs, meprins, MT-MMPs,
and FAP-
may use their proteolytic domain to form transient,
adhesive bonds with collagen of the ECM (Table 3)
. Independently of its
catalytic domain, the ectopeptidase DPPIV of epithelial-, fibroblast-,
and T-cell types binds to fibronectin and collagen in domains distinct
from each other [27
] (Fig. 1
and Table 3 ). In a
rat-lung, capillary endothelia cell model, DPPIV serves as an adhesion
molecule for breast cancer cells via tumor cell-surface-associated
fibronectin [63
].
As a consequence of their capacities to shed some cell-adhesion
molecules, it is obvious that membrane proteases affect the adhesive
properties of cells. Apart from their proteolytic domains, ADAMs
function in cell-cell adhesion through their disintegrin domains
[8
9
10
]. ADAMs can interact with integrins on adjacent
cells through their RGD sequence as an integrin ligand, as observed for
ADAM-15, which interacts with
vß3 and
5ß1 integrins on
hematopoietic cells [8
, 40
] (Table 3)
.
ADAM-2 and ADAM-9 bind to
6ß1 through their disintegrin sequence
ECD [8
, 41
, 42
] (Table 3)
.
However, in two recent studies, the integrins
vß3 and
9ß1
have been shown to interact, respectively, with ADAM-23 or ADAM-12 and
ADAM-15 through an RGD-independent mechanism [64
,
65
].
Signal transduction
Recent studies suggest that ADAMs, meprins, and ectopeptidases may
be involved in signaling.
Although no homologies with sequences found at phosphorylation acceptor sites for protein tyrosine kinases or PKC are observed in the intracellular tails of the ectopeptidases DPPIV and APN, there is evidence that ectopeptidase-mediated signal transduction involves tyrosine phosphorylation [3 ]. Molecular associations between DPPIV and other molecules such as CD45 (a tyrosine phosphatase exclusively expressed in the hematopoietic compartment) or the insulin-like growth-factor II receptor may contribute to cell activation [3 , 27 ].
The ß cytoplasmic subunit of meprins contains a consensus sequence
for phosphorylation by PKC [12
, 13
], and
the cytoplasmic tail of ADAMs (ADAMs -9, -10, -12, -15, -17, -19)
contains SH3 consensus sequences, suggesting a role in signal
transduction [8
, 9
]. However, there are no
data available presently on the specific second messengers, which could
be involved in the signals transduced by meprins and ADAMs. Recent
insights into the nervous system link ADAM and secretase activities
indirectly in Notch-mediated signaling [10
,
17
, 49
]. Notch is a transmembrane receptor
involved in the regulation of neural potential [49
]. To
be activated, Notch undergoes proteolytic cleavages, two of which
depend, respectively, on ADAM-10 (also termed KUZ) and
-secretase
activities releasing the cytoplasmic fragment of Notch, which can then
translocate to the nucleus and activate target genes [10
,
17
, 49
].
| CONCLUDING REMARKS |
|---|
|
|
|---|
The idea that emerges from the studies summarized in this review is
that a given membrane protease may have several functions (diversity)
and that more than one membrane-protease family may mediate the same
function (redundancy). Thus, the existence of different families of
membrane proteases with several and overlapping actions may be
necessary to compensate an important control system in regulating
cellular responses. During the past years, mice deficient in some
membrane proteases have been generated [3
,
10
, 66
67
68
]. These include mice deficient in
the ectopeptidases NEP, ACE, DPPIV,
-glutamyltranspeptidase
(reviewed in [3
]), ADAM-2 and -17 [10
,
66
, 67
], and MMP-9 [68
].
Although these mice have provided critical insights into in
vivo functions, there is a lack of evaluation for determining
whether these different ectoenzymes have overlapping functions in
vivo.
Overexpression and inappropriate regulation of proteolytic activity
occur often in diseases. For example, MT1-MMP of human macrophages is
over-expressed in atherosclerotic plaques [20
]. There
are many studies of the dysregulated expression of ectopeptidases in
leukocyte malignancies (leukemias, lymphomas, autoimmune diseases, HIV)
as well as in solid tumor malignancies [3
]. ß- and
-Secretases responsible for the production of APP
peptides are involved in amyloid deposition in Alzheimers disease
[14
, 17
, 49
] and are therefore
potential targets for the development of therapeutic inhibitors to
treat this disease [14
, 17
,
49
]. Mapping the proteolytic profile of human cancers and
other diseases might be valuable as an index of prognosis and as a
guide in the design of anti-proteolytic strategies aimed at controlling
progression of the disease [69
]. With regard to
ectopeptidases, ACE inhibitors have proven effective already in the
treatment of hypertension, diabetic nephropathy, and
posttransplantation erythrocytosis [3
]. As monotherapy,
NEP inhibitors have beneficial, hemodynamic effects in patients with
heart failure [3
]. A difficult issue, however, relates
to the possible overlapping activities of different proteases effective
simultaneously in some pathological situations.
Finally, soluble forms of these membrane proteases are found in biological fluids. Although their roles are still poorly understood, it may be expected that the released proteases retain their proteolytic activities and therefore add to the battery of secreted enzymes such as MMPs [70 ], elastase and cathepsin G [57 ], the plasminogen activators [58 ], and the related ADAM-TSs (ADAMs with thrombospondin-type 1 motifs) [71 ], all proteolytic enzymes involved in ECM degradation.
By addressing these issues in future studies, we should gain insight into the relationships between membrane proteases and the roles they play in physiological and pathophysiological processes.
| ACKNOWLEDGEMENTS |
|---|
Received November 20, 2000; revised January 25, 2001; accepted January 29, 2001.
| REFERENCES |
|---|
|
|
|---|
(ADAM-9) mediates cellular adhesion through
6ß1 integrin, leading to a marked induction of fibroblast cell motility J. Cell Sci. 113,2319-2328[Abstract]
-secretase: presenilin at the cutting edge Proc. Natl. Acad. Sci. USA 97,5690-5692
9ß1 to the ADAM-12 and -15 disintegrin domains mediate cell-cell interactions J. Biol. Chem. 275,34922-34930This article has been cited by other articles:
![]() |
H. Weber, A. Bernhardt, M. Dieterle, P. Hano, A. Mutlu, M. Estelle, P. Genschik, and H. Hellmann Arabidopsis AtCUL3a and AtCUL3b Form Complexes with Members of the BTB/POZ-MATH Protein Family Plant Physiology, January 1, 2005; 137(1): 83 - 93. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wu, K. H. Van der Hoek, N. K. Ryan, R. J. Norman, and R. L. Robker Macrophage contributions to ovarian function Hum. Reprod. Update, March 1, 2004; 10(2): 119 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C. Cruz, B. T. Frank, S. T. Edwards, P. F. Dazin, J. J. Peschon, and K. C. Fang Tumor Necrosis Factor-{alpha}-converting Enzyme Controls Surface Expression of c-Kit and Survival of Embryonic Stem Cell-derived Mast Cells J. Biol. Chem., February 13, 2004; 279(7): 5612 - 5620. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. McCulloch, P. Akl, H. Samaratunga, A. C. Herington, and D. M. Odorico Expression of the Disintegrin Metalloprotease, ADAM-10, in Prostate Cancer and Its Regulation by Dihydrotestosterone, Insulin-Like Growth Factor I, and Epidermal Growth Factor in the Prostate Cancer Cell Model LNCaP Clin. Cancer Res., January 1, 2004; 10(1): 314 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hahn, A. Pischitzis, S. Roesmann, M. K. Hansen, B. Leuenberger, U. Luginbuehl, and E. E. Sterchi Phorbol 12-Myristate 13-Acetate-induced Ectodomain Shedding and Phosphorylation of the Human Meprin{beta} Metalloprotease J. Biol. Chem., October 31, 2003; 278(44): 42829 - 42839. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Smith, A. Gaultier, H. Cousin, D. Alfandari, J. M. White, and D. W. DeSimone The cysteine-rich domain regulates ADAM protease function in vivo J. Cell Biol., December 9, 2002; 159(5): 893 - 902. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |